Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Suresh Ramalingam MD, FACP, FASCO

Suresh S. Ramalingam MD, FACP, FASCO

Professor of Hematology and Medical Oncology, Roberto C. Goizueta Chair for Cancer Research, Director, Division of Medical Oncology, Deputy Director, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Disclosures

Disclosures: Consultant/Scientific advisory board: Merck, Bristol Myers Squibb, Astra Zeneca, Lilly, Takeda, Eisai, Amgen, Genmab

Research support (to institution): Merck, Bristol Myers Squibb, Astra Zeneca, Lilly, Takeda, Eisai, Amgen, Genmab

Recent Contributions to PracticeUpdate:

  1. Pembrolizumab Plus Ipilimumab for Metastatic NSCLC With PD-L1 Tumor Proportion Score ≥50%

Most Read This Week

Recently Updated